Logo  


Partner area


 
  HOME About us Technologies Services Consulting Business Development
 

 

 

 

 

 

 

 

Technology



Events

Discovery & Development Europe 2025: Formulation & Drug Delivery Congress
July 1-2, 2025
Basel, Switzerland

Invited lecture:
Oral Delivery Of Peptide And Protein Drugs – Oral Delivery of GLP-1 Analogues

Prof. Dr. A. Bernkop-Schnürch
more...



8th European Cyclodextrin Conference
September 9-12, 2025
Milano, Italy

Invited lecture:
Thiolated Cyclodextrins in Drug Delivery

Prof. Dr. A. Bernkop-Schnürch
more...




 

 

 

Efflux 1Transepithelial transport of rhodamine-123 (Rho-123) in the absorptive direction in the absence (grey graph) and presence (blue graph) of thiolated chitosan at a concentration of 0.5% (m/v). Transport data are expressed as percentage of the total dose of Rho-123 (0.001% m/v) applied to the apical side of the mucosa [Werle M. and Hoffer M. (2005) Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Rel., 111, 41].

Efflux 2Transepithelial transport of sulforhodamine 101 (sRho) in the absorptive direction in the absence (grey bars) and presence (blue bars) of thiolated poly(-acrylic acid) (PAA) of indicated molecular mass at a concentration of 0.5% (m/v) [Grabovac V., Bernkop-Schnürch A. (2006) Thiolated polymers as effective inhibitors   of   intestinal   Mrp2    efflux    pump transporters, Scientia Pharmaceutica 74, 75].

 

 

Efflux Pump Inhibition


As shown in the Figure below transmucosal transport of the P-gp substrate rhodamine 123 (grey graph) is strongly improved in the presence of thiolated chitosan [Werle M., and Hoffer M. (2005). Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Rel., 111, 41]. These in vitro results could meanwhile be confirmed by various in vivo studies with various efflux pump substrates. Föger et al., for instance, showed that the oral bioavailability of rhodamine 123 is even 3.0- fold improved when this model P-gp substrate is embedded in thiolated chitosan minitablets given orally to rats [Föger F., Schmitz T., and Bernkop-Schnürch A. (2006) In vivo evaluation of polymeric delivery systems for P-glycoprotein substrates. Biomaterials, 27, 4250].
In addition, poly(acrylic acid)-cysteine conjugate showed to inhibit effectively Mrp2 efflux pump transporter, improving the permeation of sulforhodamine 101 4.67-fold [Grabovac V., Bernkop-Schnürch A. (2006) Thiolated polymers as effective
inhibitors of intestinal Mrp2 effluxpump transporters, Scientia Pharmaceutica 74, 75].
The postulated mechanism of efflux pump inhibition is based on an interaction of thiomers with the channel forming transmembrane domain of various efflux pumps such as P-gp and multidrug resistance proteins (MRPs). P-gp, for instance, exhibits 12 transmembrane regions forming a channel through which substrates are transported outside of the cell. Two of these transmembrane domains – namely 2 and 11 – exhibit on position 137 and 956, respectively, a cysteine subunit. Thiomers seem to enter in the channel of P-gp and likely form subsequently one or two disulfide bonds with one or both cysteine subunits located within the channel. Due to this covalent interaction the allosteric change of the transporter being essential to move drugs outside of the cell might be blocked
[Gottesman M.M. and Pastan I. (1988). The multidrug transporter, a double-edged sword. J. Biol. Chem., 263, 12163].

 


Download a brochure

  News

Thiomatrix joined the EU-project TENTACLE (101191747) focusing on the use of thiomers for in situ bioprinting.
more....

 

Contact

 

Careers
Downloads
Site map

a



ThioMatrix Hotline:
+43 512 890046
Mo-Th 9.00-17.00
and Fr 9.00-14.00


Drucker Print this page

 

Download references about thiomers

 

 

 

 

     

© All rights reserved | Site map | Disclaimer | Imprint | Contact |

 

GR

TM